Prediction of glycyrrhizin disposition in rat and man by a physiologically based pharmacokinetic model.

Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat.

A physiologically-based pharmacokinetic model for disposition of 2,3,7,8-TCDD in fathead minnow and medaka.

Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.

A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children.

Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.

A physiologically-based pharmacokinetic model for absorption of oral paracetamol in man [proceedings].

A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly population.

A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid.

Interspecies extrapolation by physiologically based pharmacokinetic modeling.

Development of a physiologically-based pharmacokinetic model of the rat central nervous system.

Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.

Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.

Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.

A physiologically based toxicokinetic model for the uptake and disposition of waterborne organic chemicals in fish.

Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction.

Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.

A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.

A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.

Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model.

Suggest Documents

Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat.

A physiologically-based pharmacokinetic model for disposition of 2,3,7,8-TCDD in fathead minnow and medaka.

Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.

A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children.

Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.

A physiologically-based pharmacokinetic model for absorption of oral paracetamol in man [proceedings].

A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly population.

A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid.

Interspecies extrapolation by physiologically based pharmacokinetic modeling.

Development of a physiologically-based pharmacokinetic model of the rat central nervous system.

Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.

Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.

Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.

A physiologically based toxicokinetic model for the uptake and disposition of waterborne organic chemicals in fish.

Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction.

Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.

A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.

A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.

Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model.

Prediction of glycyrrhizin disposition in rat and man by a physiologically based pharmacokinetic model.

Recommend Documents

Follow Us